Drugs / Taltirelin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04107740 | Mar 2019 → Feb 2021 | cerebellar degeneration | HLB Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Taltirelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04107740 ↗ |
| Known as | TA-0910 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107016 ↗ |
| Known as | Taltirelina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107016 ↗ |
| Known as | Taltireline | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107016 ↗ |
| Action | Activate | “Thyrotropin-releasing hormone receptor agonist” CHEMBL2107016 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2107016 ↗ |
| Target | TRHR | “Thyrotropin-releasing hormone receptor agonist” CHEMBL2107016 ↗ |